Annual Best Practice in Phase IV Clinical & Observational Research 2010

Phase IV clinical trials are one the fastest growing areas of clinical research. Such post-marketing studies are becoming increasingly important as regulatory agencies demand more long-term data which proves efficacy, safety and quality. Furthermore, a key driver is the demands of health technology assessors and payers and their need for evidence-based economic data, again over the long-term. However, as post-marketing studies tend to be more commercial in nature, successfully planning and implementing them can be a major challenge, especially in terms of motivating investigators and recruiting patients who may already have access to the latest medications.

The event will provide the latest and most valuable, real-life experiences in post-marketing studies, their benefits and challenges. It will be an ideal opportunity for benchmarking and networking with the experts.

Why Attend?

ü Gain access to the latest methodologies and real-life cases in the field.

ü Explore how market leaders are improving data accuracy.

ü Balancing conflicting scientific, regulatory & marketing needs.

ü Learn more about comparative studies and their value for drug safety.

ü Understand how key figures are affecting future trends and standards.

ü Understand regulatory / ethical priorities.

ü Find out how phase IV studies & observational research are being outsourced and how industry players are selecting the right partners.

Who will benefit?

Pharmaceutical & Biotech companies Vice Presidents, Directors & Managers of: Medical Affairs, Epidemiology, Clinical Development & Operations, Drug Safety, Pharmacovigilance, Data Management, Regulatory Affairs, Clinical Outsourcing

Solution Providers: CROs, EDC & Data Management, Clinical Software, Market Access & Health Outcomes Consultancies

Academics & Doctors: Epidemiology, Principle Investigators, Primary Care<br /